💊 Novo Nordisk expands distribution of Wegova via telehealth. Hims & Hers shares jumped by more than 25%!
Danish pharmaceutical giant Novo Nordisk $NVO is coming up with another move to accelerate sales of its weight loss drug Wegova. The drug will now also be available through telemedicine platforms such as Hims & Hers Health $HIMS, LifeMD, and including NovoCare's direct online pharmacy .

📈 An important step at an exciting time:
FDA ends ability to mass produce unapproved generic versions of Wegova
Obesity drug marketexperiences huge surge in demand
Wegovaitself is no longer a scarce commodity in the U.S., opening up room to more aggressively recruit patients

Stock Reaction:
Hims & Hers +30% (biggest daily increase in months)
Novo Nordisk +5% (growth after several months of declines)

📊 Pricing and access for patients:
NovoCare offers Wegova for $499/month, half the standard list price.

Hims & Hers offers a comprehensive package (benefits, continuing care, nutritional counseling) starting at $599/month.

🎯 For Novo Nordisk, telehealth marks an important expansion:
Direct access to patients at a time when the regulatory environment is tightening the noose around generics

More precise control over the distribution of the original medicine

The ability to optimise pricing strategy without pressure from chain pharmacies.

For Hims & Hers and other players:
Opportunity to differentiate in the marketplace with quality care and branded medicine instead of substitutes

Access to one of today's most in-demand pharmaceutical products.

What do you think of Novo Nordisk, will it change the current trend? How do you like the telemedicine sector?